ERBB2 and breast cancer: The antibody–drug conjugate of trastuzumab deruxtecan against Her2 has shown activity in clinically Her2 negative breast cancers with low Her2 expression (i.e., IHC 1 + or 2 + with lack of ERBB2 amplification) [157, 158].